Myriad Genetics, Inc.
(NASDAQ : MYGN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen Inc.
0.17%358.711.2%$830.53m
AMGNAmgen Inc.
-0.66%190.491.2%$543.11m
CELGCelgene Corporation
-0.28%85.101.2%$507.54m
GILDGilead Sciences, Inc.
0.42%77.370.9%$473.45m
VRTXVertex Pharmaceuticals Incorporated
-1.51%177.401.9%$313.54m
REGNRegeneron Pharmaceuticals, Inc.
-0.17%367.112.6%$276.88m
ILMNIllumina, Inc.
0.66%311.153.5%$269.38m
BLUEBluebird Bio, Inc.
0.78%180.3515.7%$197.52m
SRPTSarepta Therapeutics, Inc.
-1.64%133.3116.6%$196.81m
ALXNAlexion Pharmaceuticals, Inc.
0.05%135.162.0%$178.57m
NKTRNektar Therapeutics
-0.71%48.735.6%$172.03m
EXASExact Sciences Corporation
0.02%67.6225.4%$155.70m
EXELExelixis, Inc.
-0.23%21.296.4%$135.36m
BMRNBioMarin Pharmaceutical Inc.
-0.94%101.904.4%$122.64m
AAgilent Technologies, Inc.
-0.45%63.861.5%$110.57m

Company Profile

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through two segments: Diagnostics and Other. The Diagnostics segment engages in the provision of testing that is designed to assess the risk for developing disease later in life of the patient, identify the likelihood of responding to drug therapy and guide the dosing to ensure optimal treatment, or assess a the disease progression and disease recurrence of the patient. The Other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients. The company was founded by Walter A. Gilbert, Mark H. Skolnick and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake, UT.